Author(s): Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, , Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F,
Abstract Share this page
Abstract BACKGROUND & AIMS: To better evaluate the HIV-HCV co-infection burden in the context of new effective HCV treatment. METHODS: We reviewed all the epidemiological data available on HCV-related disease in HIV-infected patients in France. Sources of data have been selected using the following criteria: (i) prospective cohorts or cross-sectional surveys; (ii) conducted at a national level; (iii) in the HIV-infected population; (iv) able to identify HCV co-infection and chronic active hepatitis C (HCV RNA positive); and (v) conducted during the period 2003-2012. RESULTS: The overall prevalence of HIV-HCV co-infection has decreased from 22-24\% to 16-18\%. This prevalence decreased from 93\% to 87\% among injecting drug users while it increased from 4\% to 6\% among men who have sex with men. The characteristics of patients have changed: decrease in the proportion of patients with chronic active hepatitis C (HCV RNA positive) from 77\% to 63\% and in the genotypes 2 and 3 HCV infection; increase in the proportion of HCV genotype 1 (from 45-50\% to 58\%) and genotype 4 (from 15\% to 22\%). The proportion of patients treated with highly active antiretroviral therapy increased from 76\% to 95\%, with higher rates of undetectable HIV viral load (47\% in 2004 vs. 85\% in 2012). CONCLUSION: The decreasing prevalence and the change in patients profile in HIV-HCV co-infection underline the importance of continuing efforts to educate physicians and patients. This should increase the benefit of viral risk reduction policies and increase the access of co-infected patients to HCV treatment. © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
This article was published in Liver Int
and referenced in Journal of AIDS & Clinical Research